Related references
Note: Only part of the references are listed.Oral Uracil and Tegafur Compared With Classic Cyclophosphamide, Methotrexate, Fluorouracil As Postoperative Chemotherapy in Patients With Node-Negative, High-Risk Breast Cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial
Toru Watanabe et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer
Hyman B. Muss et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Progress and promise:: highlights of the international expert consensus on the primary therapy of early breast cancer 2007
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2007)
Additive antitumor effect of concurrent treatment of 4-hydroxy tamoxifen with 5-fluorouracil but not with doxorubicin in estrogen receptor-positive breast cancer cells
Junichi Kurebayashi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy
R Munoz et al.
CANCER RESEARCH (2006)
Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: A pooled analysis of six randomized controlled trials
S Noguchi et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Meta-analysis of five studies on tegafur plus uracil (UFT) as post-operative adjuvant chemotherapy for breast cancer
F Kasumi et al.
ONCOLOGY (2003)
Share Paper
